{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:21:06Z","timestamp":1781230866651,"version":"3.54.1"},"reference-count":40,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.2016.0799","type":"journal-article","created":{"date-parts":[[2018,5,2]],"date-time":"2018-05-02T09:27:14Z","timestamp":1525253234000},"source":"Crossref","is-referenced-by-count":11,"title":["Antiviral Medications in Seasonal and Pandemic Influenza"],"prefix":"10.3238","author":[{"given":"Regine","family":"Lehnert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annicka","family":"Reuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Schaberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2016,11,25]]},"reference":[{"key":"10.3238\/arztebl.2016.0799_ref1","unstructured":"European Medicines Agency: Updated review of influenza antiviral medicinal products for potential use during pandemic by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA). www.ema.europa.eu\/docs\/en_GB\/document_library\/Report\/2009\/11\/WC500011117.pdf (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref2","unstructured":"World Health Organization: WHO Guidelines for Pharmacological Management of Pandemic Influenza A(H1N1) 2009 and other influenza viruses. www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_guidelines_pharmaceutical_mngt.pdf (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref3","unstructured":"Robert Koch-Institut: Nationaler Pandemieplan.www.rki.de\/DE\/Content\/InfAZ\/I\/Influenza\/Pandemieplanung\/Nationaler_Influenzapan demieplan.html (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref4","unstructured":"Meyer R: Tamiflu: Eine unendliche Geschichte um Datentransparenz. Dtsch Arztebl 2013; 110: A-132"},{"key":"10.3238\/arztebl.2016.0799_ref5","unstructured":"Meyer R: Neue Meta-Analyse stellt Wirkung infrage. Dtsch Arztebl. www.aerzteblatt.de\/nachrichten\/58300 (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref6","unstructured":"World Health Organization: WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. www.who.int\/csr\/resources\/publications\/swineflu\/h1n1_use_antivirals_20090820\/en\/ (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref7","unstructured":"European Centers for Disease Control: Draft scientific advice for consulation. ECDC preliminary scientific advice. Expert opinion on neuraminidase inhibitors for prevention and treatment of influenza. Review of recent systematic reviews and meta-analyses. http:\/\/ecdc.europa.eu\/en\/publications\/publications\/neuraminidase-inhibitors-flu-consultation.pdf (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref8","unstructured":"Centers for Disease Control: Antiviral drugs-information for health care professionals. www.cdc.gov\/flu\/professionals\/antivirals\/index.htm (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref9","unstructured":"Public Health England: Guidance. Influenza: treatment and prophylaxis using anti-viral agents. www.gov.uk\/government\/publications\/influenza-treatment-and-prophylaxis-using-anti-viral-agents (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref10","doi-asserted-by":"crossref","unstructured":"Ewig S, H\u00f6ffken G, Kern WV, et al.: Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie und Pr\u00e4vention \u2013 Update 2016. Pneumologie 2016; 70: 151\u2013200","DOI":"10.1055\/s-0042-101873"},{"key":"10.3238\/arztebl.2016.0799_ref11","doi-asserted-by":"crossref","unstructured":"Michiels B, Van Puyenbroeck K, Verhoeven V, Vermeire E, Coenen S: The value of neuraminidase inhibitors for the prevention and treatment of seasonal influenza: a systematic review of systematic reviews. PloS One 2013; 8: e60348","DOI":"10.1371\/journal.pone.0060348"},{"key":"10.3238\/arztebl.2016.0799_ref12","doi-asserted-by":"crossref","unstructured":"Tappenden P, Jackson R, Cooper K, et al.: Amantadine, oseltamivir and zanamivir for the prophylaxis of influenza (including a review of existing guidance no. 67): a systematic review and economic evaluation. Health Technol Assess 2009; 13: iii, ix-xii, 1\u2013246","DOI":"10.3310\/hta13110"},{"key":"10.3238\/arztebl.2016.0799_ref13","doi-asserted-by":"crossref","unstructured":"Jackson RJ, Cooper KL, Tappenden P, et al.: Oseltamivir, zanamivir and amantadine in the prevention of influenza: a systematic review. J Infect 2011; 62: 14\u201325","DOI":"10.1016\/j.jinf.2010.10.003"},{"key":"10.3238\/arztebl.2016.0799_ref14","doi-asserted-by":"crossref","unstructured":"Khazeni N, Bravata DM, Holty JE, Uyeki TM, Stave CD, Gould MK: Systematic review: safety and efficacy of extended-duration antiviral chemoprophylaxis against pandemic and seasonal influenza. Ann Intern Med 2009; 151: 464\u201373","DOI":"10.7326\/0003-4819-151-7-200910060-00143"},{"key":"10.3238\/arztebl.2016.0799_ref15","doi-asserted-by":"crossref","unstructured":"Jefferson T, Jones MA, Doshi P, et al.: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2014; 4: CD008965","DOI":"10.1002\/14651858.CD008965.pub4"},{"key":"10.3238\/arztebl.2016.0799_ref16","doi-asserted-by":"crossref","unstructured":"Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D: Amantadine and rimantadine for influenza A in adults. Cochrane Database Syst Rev 2006; (2): CD001169","DOI":"10.1002\/14651858.CD001169.pub3"},{"key":"10.3238\/arztebl.2016.0799_ref17","doi-asserted-by":"crossref","unstructured":"Alves Galvao MG, Rocha Crispino Santos MA, Alves da Cunha AJ: Amantadine and rimantadine for influenza A in children and the elderly. Cochrane Database Syst Rev 2014; 11: CD002745","DOI":"10.1002\/14651858.CD002745.pub4"},{"key":"10.3238\/arztebl.2016.0799_ref18","doi-asserted-by":"crossref","unstructured":"Wang K, Shun-Shin M, Gill P, Perera R, Harnden A: Neuraminidase inhibitors for preventing and treating influenza in children (published trials only). Cochrane Database Syst Rev 2012; 4: CD002744","DOI":"10.1002\/14651858.CD002744.pub4"},{"key":"10.3238\/arztebl.2016.0799_ref19","doi-asserted-by":"crossref","unstructured":"Ison MG, Szakaly P, Shapira MY, Krivan G, Nist A, Dutkowski R: Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients. Antivir Ther 2012; 17: 955\u201364","DOI":"10.3851\/IMP2192"},{"key":"10.3238\/arztebl.2016.0799_ref20","doi-asserted-by":"crossref","unstructured":"Monto AS, Pichichero ME, Blanckenberg SJ, et al.: Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis 2002; 186: 1582\u20138","DOI":"10.1086\/345722"},{"key":"10.3238\/arztebl.2016.0799_ref21","doi-asserted-by":"crossref","unstructured":"Burch J, Paulden M, Conti S, et al.: Antiviral drugs for the treatment of influenza: a systematic review and economic evaluation. Health Technol Assess 2009; 13: 1\u2013265, iii\u2013iv","DOI":"10.3310\/hta13580"},{"key":"10.3238\/arztebl.2016.0799_ref22","doi-asserted-by":"crossref","unstructured":"Dobson J, Whitley RJ, Pocock S, Monto AS: Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015; 385: 1729\u201337","DOI":"10.1016\/S0140-6736(14)62449-1"},{"key":"10.3238\/arztebl.2016.0799_ref23","doi-asserted-by":"crossref","unstructured":"Muthuri SG, Venkatesan S, Myles PR, et al.: Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data. Lancet Respir Med 2014; 2: 395\u2013404","DOI":"10.1016\/S2213-2600(14)70041-4"},{"key":"10.3238\/arztebl.2016.0799_ref24","doi-asserted-by":"crossref","unstructured":"Freemantle N, Shallcross LJ, Kyte D, Rader T, Calvert MJ: Oseltamivir: the real world data. BMJ 2014; 348: g2371","DOI":"10.1136\/bmj.g2371"},{"key":"10.3238\/arztebl.2016.0799_ref25","doi-asserted-by":"crossref","unstructured":"Jefferson T, Jones MA, Doshi P, et al.: Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012; 1: CD008965","DOI":"10.1002\/14651858.CD008965.pub3"},{"key":"10.3238\/arztebl.2016.0799_ref26","doi-asserted-by":"crossref","unstructured":"Lipsitch M, Hernan MA: Oseltamivir and risk of lower respiratory tract complications in patients with flu symptoms: a meta-analysis of eleven randomized clinical trials. Clin Infect Dis 2011; 53: 277\u20139","DOI":"10.1093\/cid\/cir400"},{"key":"10.3238\/arztebl.2016.0799_ref27","doi-asserted-by":"crossref","unstructured":"Muthuri SG, Myles PR, Venkatesan S, Leonardi-Bee J, Nguyen-Van-Tam JS: Impact of neuraminidase inhibitor treatment on outcomes of public health importance during the 2009\u20132010 influenza A(H1N1) pandemic: a systematic review and meta-analysis in hospitalized patients. J Infect Dis 2013; 207: 553\u201363","DOI":"10.1093\/infdis\/jis726"},{"key":"10.3238\/arztebl.2016.0799_ref28","unstructured":"Muthuri SG, Venkatesan S, Myles PR, et al.: Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses 2016: 192\u2013204"},{"key":"10.3238\/arztebl.2016.0799_ref29","doi-asserted-by":"crossref","unstructured":"Fry AM, Goswami D, Nahar K, et al.: Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis 2014; 14: 109\u201318","DOI":"10.1016\/S1473-3099(13)70267-6"},{"key":"10.3238\/arztebl.2016.0799_ref30","doi-asserted-by":"crossref","unstructured":"Jefferson T, Jones M, Doshi P, Del Mar C, Dooley L, Foxlee R: Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2010: CD001265","DOI":"10.1002\/14651858.CD001265.pub3"},{"key":"10.3238\/arztebl.2016.0799_ref31","doi-asserted-by":"crossref","unstructured":"Nicholson KG, Aoki FY, Osterhaus AD, et al.: Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845\u201350","DOI":"10.1016\/S0140-6736(00)02288-1"},{"key":"10.3238\/arztebl.2016.0799_ref32","doi-asserted-by":"crossref","unstructured":"Aoki FY, Macleod MD, Paggiaro P, et al.: Early administration of oral oseltamivir increases the benefits of influenza treatment. J Antimicrob Chemother 2003; 51: 123\u20139","DOI":"10.1093\/jac\/dkg007"},{"key":"10.3238\/arztebl.2016.0799_ref33","doi-asserted-by":"crossref","unstructured":"Adisasmito W, Chan PK, Lee N, et al.: Effectiveness of antiviral treatment in human influenza A(H5N1) infections: analysis of a global patient registry. J Infect Dis 2010; 202: 1154\u201360","DOI":"10.1086\/656316"},{"key":"10.3238\/arztebl.2016.0799_ref34","doi-asserted-by":"crossref","unstructured":"Bautista E, Chotpitayasunondh T, Gao Z, et al.: Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708\u201319","DOI":"10.1056\/NEJMra1000449"},{"key":"10.3238\/arztebl.2016.0799_ref35","doi-asserted-by":"crossref","unstructured":"Anekthananon T, Pukrittayakamee S, Ratanasuwan W, et al.: Oseltamivir and inhaled zanamivir as influenza prophylaxis in Thai health workers: a randomized, double-blind, placebo-controlled safety trial over 16 weeks. J Antimicrob Chemother 2013; 68: 697\u2013707","DOI":"10.1093\/jac\/dks418"},{"key":"10.3238\/arztebl.2016.0799_ref36","unstructured":"European Medicines Agency: Tamiflu product information. www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000402\/human_med_001075.jsp&mid=WC0b01ac058001d124 (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref37","unstructured":"L\u00e4kemedelsverket, Medical Products Agency: Relenza product information. https:\/\/lakemedelsverket.se\/LMF\/Lakemedelsinformation\/?nplid=19990209000018&type=product (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref38","unstructured":"Pharmnet.Bund: Fachinformation Relenza. www.pharmnet-bund.de\/dynamic\/de\/arzneimittel-informationssystem\/index.html (last accessed on 20 September 2016)."},{"key":"10.3238\/arztebl.2016.0799_ref39","doi-asserted-by":"crossref","unstructured":"Meijer A, Lackenby A, Hungnes O, et al.: Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007\u201308 season. Emerg Infect Dis 2009; 15: 552\u201360","DOI":"10.3201\/eid1504.181280"},{"key":"10.3238\/arztebl.2016.0799_ref40","doi-asserted-by":"crossref","unstructured":"Jagannath VA, Asokan GV, Fedorowicz Z, Lee TW: Neuraminidase inhibitors for the treatment of influenza infection in people with cystic fibrosis. Cochrane Database Syst Rev 2014; 2: CD008139","DOI":"10.1002\/14651858.CD008139.pub3"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0799","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T14:04:22Z","timestamp":1638799462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.2016.0799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,25]]},"references-count":40,"URL":"https:\/\/doi.org\/10.3238\/arztebl.2016.0799","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,25]]}}}